by Peter Ciszewski | Jan 9, 2019
Editor’s Note: This interview was conducted at #Bio2018. Please pardon the background noise. Brian Schwartz, Chief Medical Officer of ArQule, discusses his company focus on Proteus syndrome, a rare condition characterized by overgrowth of the bones, skin,...
by Peter Ciszewski | Jan 8, 2019
Amy Burd, PhD, Vice President of Research Strategy at the Leukemia and Lymphoma Society (LLS), discusses her group’s multiarm, multisite collaborative trial which aims to test targeted therapy approaches for improving the generally poor prognosis among...
by Peter Ciszewski | Jan 7, 2019
Rod Humerickhouse, MD, PhD, asset strategy leader at AbbVie discusses the potential use of venetoclax for the treatment of patients with multiple myeloma at the 60th ASH Annual Meeting in San Diego. Multiple myeloma is a cancer of plasma cells. Normal plasma...
by Peter Ciszewski | Jan 4, 2019
The Food and Drug Administration (FDA) approved Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients aged ≥1 year with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Sprycel, a second...
by Peter Ciszewski | Jan 3, 2019
Carol Satler, MD Vice President of Medical Affairs in North America for Sobi, discusses the ultra rare disease primary haemophagocytic lymphohistiocytosis (HLH) and a new FDA approved treatment Emapalumab. HLH is an often-fatal syndrome of hyperinflammation in...
